[{"id":"60bc510e-dedf-43a0-9348-c4b613d7820b","acronym":"","url":"https://clinicaltrials.gov/study/NCT05684211","created_at":"2023-01-13T14:59:08.962Z","updated_at":"2024-07-02T16:35:56.611Z","phase":"Phase 2b","brief_title":"A Study of Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer","source_id_and_acronym":"NCT05684211","lead_sponsor":"Shanghai Celfuture Biotech Co., Ltd.","biomarkers":" KRAS • NRAS • RAS","pipe":" | ","alterations":" KRAS wild-type • NRAS wild-type","tags":["KRAS • NRAS • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • irinotecan • leucovorin calcium • amelimumab (SY101)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 84","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 01/01/2023","primary_completion_date":" 01/01/2023","study_txt":" Completion: 01/01/2023","study_completion_date":" 01/01/2023","last_update_posted":"2023-02-01"}]